Vaccine Name: Adjuvant recombinant vaccine candidate
Company: Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences
A subsequent phase 2 clinical trial is actively recruiting and will enroll 900 subjects. They will be randomly divided into groups that will receive either: 2 doses of a low-dose vaccine, 2 doses of a high-dose vaccine, 2 doses of placebo, 3 doses of low-dose vaccine, 3 doses of high-dose vaccine, or 3 doses of placebo.
Vaccine Name: Ad5-nCoV
Company: CanSino Biologics
Update: This adenovirus type 5 vector vaccine candidate has made its way through a phase 1 trial that included 108 adult participants that received low, medium, and high doses of the vaccine. Results published in The Lancet described significantly increased antibodies by day 14 post-vaccination with a peak at 28 days post-vaccination. T-cell response peaked at 14 days post-vaccination, the study authors wrote. Side effects included pain, fever, fatigue, headache, and muscle pain present in a majority of patients.
Vaccine Name: Ad26.COV2.S
Company: Johnson & Johnson (Janssen)
Update: Johnson & Johnson announced that its drug development wing, Janssen Pharmaceutical, has reached an agreement with the US Biomedical Advanced Research and Development Authority (BARDA) for the large scale manufacturing and delivery of 100 million doses of Ad26.COV2.S, an adenovirus-based SARS-CoV-2 investigational vaccine.
October 12: J&J paused their clinical trials due to an unexplained illness in a vaccine participant.
Vaccine Name: BBIBP-CorV
Company: Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)
Update: This is the second of Sinopharm’s inactivated COVID-19 vaccine candidates. Study authors wrote in Cell that 2 doses of this candidate induced high levels of antibodies in animal models, including macaques, and seemed to be safe.
Vaccine Name: GX-19
Update: GX-19 is a DNA vaccine candidate from South Korean-based biotechnology company Genexine, 1 of 3 companies supported by the Korean government. On August 19, it was reported the vaccine showed defense and resistance efficacy against the Covid-19 virus in two primates.